natgillin/translations-raw huggingface dataset:
In the present application, the applicant proposed that, in order to bear the claim, a product should contain a dose of caffeine of at least 40 mg per serving.
Agencija je v svojem mnenju opozorila, da je trditev o kofeinu in večji budnosti pri splošnem odraslem prebivalstvu za izdelke, ki vsebujejo vsaj 75 mg kofeina na porcijo, že ugodno ocenila [3].
The Authority considered that the scientific substantiation of this claim related to doses of caffeine between 40 mg per serving [4] and 75 mg per serving [5], and concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of caffeine and increased alertness under the conditions of use proposed by the applicant.
Vložnik v okviru te vloge predlaga, da mora izdelek za navedbo trditve vsebovati vsaj 40 mg odmerka kofeina na porcijo.
Further, the Authority reiterated its previous conclusion that, in order to bear the claim, a product should contain at least 75 mg caffeine per serving.
Agencija je menila, da se je znanstvena utemeljitev te trditve nanašala na kofein v odmerku med 40 mg [4] in 75 mg na porcijo [5], in sklenila, da je na podlagi predloženih podatkov vzročno-posledična povezava med uživanjem kofeina in večjo budnostjo v skladu s pogoji uporabe, ki jih je predlagal vložnik.
Accordingly, as the claim, under the proposed conditions of use, does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Nadalje je Agencija poudarila svojo predhodno ugotovitev, da mora izdelek za navedbo trditve vsebovati vsaj 75 mg kofeina na porcijo.
Following an application from BASF SE and Stepan Lipid Nutrition, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to an equimolar mixture (marketed under the trade names Clarinol® and Tonalin®) of the two conjugated linoleic acid (CLA) isomers c9,t11 and t10,c12, and contribution to a reduction in body fat mass (Question No EFSA-Q-2014-00580 [6]).
Ker zdravstvena trditev pod predlaganimi pogoji uporabe ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
The claim proposed by the applicant was worded as follows: ‘Consumption of Clarinol® or Tonalin® contributes to a reduction in body fat mass’.
Družbi BASF SE in Stepan Lipid Nutrition sta v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložili vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki ekvimolarne mešanice (ki se trži pod blagovnima znamkama Clarinol® in Tonalin®) obeh izomerov konjugiranih linolnih kislin (CLA) c9,t11 in t10,c12 in zmanjšanju telesne maščobe (vprašanje št.
On 8 January 2015, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of an equimolar mixture of the CLA isomers c9,t11 and t10,c12, marketed under the trade names of Clarinol® and Tonalin®, and the claimed effect.
EFSA-Q-2014-00580 [6]).
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Vložnik je predlagal naslednjo trditev: „Uživanje izdelkov Clarinol® ali Tonalin® prispeva k zmanjšanju telesne maščobe.“
Following an application from Synbiotec S.r.l., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to SYNBIO®, a combination of Lactobacillus rhamnosus IMC 501® and Lactobacillus paracasei IMC 502®, and maintenance of normal defecation (Question No EFSA-Q-2014-00567 [7]).
Komisija in države članice so 8. januarja 2015 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem ekvimolarne mešanice CLA izomerov c9,t11 in t10,c12, ki se trži pod blagovnima znamkama Clarinol® in Tonalin®, in navedeno trditvijo ni utemeljena.
The claim proposed by the applicant was worded as follows: ‘SYNBIO® persists in the intestinal tract and favours the natural regularity contributing to maintain and improve human intestinal well-being’.
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
On 13 May 2015, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of SYNBIO® and maintenance of normal defecation.
Družba Synbiotec S.r.l. je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z izdelkom SYNBIO®, kombinacijo Lactobacillus rhamnosus IMC 501® in Lactobacillus paracasei IMC 502®, in vzdrževanju normalnega odvajanja blata (vprašanje št.
Following an application from WILD-Valencia SAU, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to a FRUIT UP®, a carbohydrate extract from carob pods (Ceratonia siliqua L.), and a reduction of post-prandial blood glucose responses (Question No EFSA-Q-2014-00405 [8]).
EFSA-Q-2014-00567 [7]).
The claim proposed by the applicant was worded as follows: ‘FRUIT UP® reduces post-prandial blood glucose responses compared to high-glycaemic carbohydrates’.
Vložnik je predlagal naslednjo trditev: „SYNBIO® ostane v prebavnem traktu in ohranja redno prebavo, kar prispeva k ohranjanju in izboljšanju delovanja človeškega črevesja.“
On 13 May 2015, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of FRUIT UP® and a reduction of post-prandial glycaemic responses over and above the well-established effect of fructose [9] on reducing post-prandial glycaemic responses when replacing glucose in foods.
Komisija in države članice so 13. maja 2015 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izdelka SYNBIO® in ohranjanjem normalnega odvajanja blata ni utemeljena.
The Authority also stated that no effect had been observed when FRUIT UP® was compared with sucrose.
Družba WILD-Valencia SAU je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z izdelkom FRUIT UP®, izvlečkom ogljikovih hidratov iz rožičevih strokov (Ceratonia siliqua L.), in zmanjšanjem postprandialnega glikemičnega odziva (vprašanje št.
Following an application from Nerthus ApS, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to a combination of pomegranate pomace extract (standardised by its content of punicalagins) and greater galangal rhizome powder (standardised by its content of acetoxychavicol acetate) and an increase in the number of motile spermatozoa in semen (Question No EFSA-Q-2014-00566 [10]).
EFSA-Q-2014-00405 [8]).
The claim proposed by the applicant was worded as follows: ‘A combination of standardised pomegranate pomace extract and greater galangal rhizome powder increases the number of motile spermatozoa in semen’.
Vložnik je predlagal naslednjo trditev: „FRUIT UP® zmanjša postprandialni glikemični odziv v primerjavi z visokoglikemičnimi ogljikovimi hidrati“.
On 13 May 2015, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of the combination of pomegranate pomace extract (standardised by its content of punicalagins) and greater galangal rhizome powder (standardised by its content of acetoxychavicol acetate) and the claimed effect.
Komisija in države članice so 13. maja 2015 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izdelka FRUIT UP® in zmanjšanjem postprandialnega glikemičnega odziva nižje od fruktoze, za katero je ta učinek dobro znan [9], kadar nadomešča glukozo v hrani, ni utemeljena.
Following an application from Lallemand Health Solutions, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Bifidobacterium bifidum CNCM I-3426 and defence against pathogens in the upper respiratory tract (Question No EFSA-Q-2014-00673 [11]).
Agencija je tudi navedla, da ni bilo učinka, ko so izdelek FRUIT UP® primerjali s saharozo.
The claim proposed by the applicant was worded as follows: ‘Bifidobacterium bifidum CNCM I-3426 increases the proportion of healthy days by maintaining normal immune function in healthy adults during everyday life events such as moderate stress’.
Družba Nerthus ApS je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki kombinacije izvlečka iz tropin granatnega jabolka (standardiziran glede na vsebnost punikalagina) in korenike velikega galangala v prahu (standardiziran glede na vsebnost acetoksikavikol acetata) in povečanjem števila gibljivih semenčic v spermi (vprašanje št.
On 13 May 2015, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of B. bifidum CNCM I-3426 and defence against pathogens in the upper respiratory tract.
EFSA-Q-2014-00566 [10]).
Following an application from Tchibo GmbH, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to coffee C21, a coffee standardised by its content of caffeoylquinic acids, trigonelline and N-methylpyridinium, and reduction of DNA damage by decreasing spontaneous DNA strand breaks (Question No EFSA-Q-2014-00624 [12]).
Vložnik je predlagal naslednjo trditev: „Kombinacija standardiziranega izvlečka iz tropin granatnega jabolka in korenike velikega galangala v prahu povečuje število gibljivih semenčic v spermi.“
The claim proposed by the applicant was worded as follows: ‘Regular consumption of coffee C21 contributes to the maintenance of DNA integrity in cells of the body’.
Komisija in države članice so 13. maja 2015 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem kombinacije izvlečka iz tropin granatnega jabolka (standardiziran glede na vsebnost punikalagina) in korenike velikega galangala v prahu (standardiziran glede na vsebnost acetoksikavikol acetata) ter navedeno trditvijo ni utemeljena.
On 13 May 2015, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of coffee C21 and the claimed effect.
Družba Lallemand Health Solutions je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z izdelkom Bifidobacterium bifidum CNCM I-3426 in obrambo pred patogeni v zgornjih dihalnih poteh (vprašanje št.
The comments from the applicants received by the Commission pursuant to Article 16(6) of Regulation (EC) No 1924/2006 have been considered when setting the measures provided for in this Regulation.
EFSA-Q-2014-00673 [11]).
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
Vložnik je predlagal naslednjo trditev: „Bifidobacterium bifidum CNCM I-3426 poveča število dni, ko smo zdravi, z ohranjanjem pravilnega delovanja imunskega sistema pri zdravih odraslih osebah pri vsakdanjih življenjskih dogodkih, kot je zmeren stres.“
HAS ADOPTED THIS REGULATION:
Komisija in države članice so 13. maja 2015 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izdelka B. bifidum CNCM I-3426 in obrambo proti patogenom v zgornjih dihalnih poteh ni utemeljena.
Article 1
Družba Tchibo GmbH je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z uživanjem kave C21, tj. kave, standardizirane po vsebnosti kafeoilkininske kisline, trigonelina in N-metilpiridinija, in zmanjšanjem poškodb DNK z zmanjšanjem spontanega trganja verige DNK (vprašanje št.
The health claims listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.
EFSA-Q-2014-00624 [12]).
Article 2
Vložnik je predlagal naslednjo trditev: „Redno uživanje kave C21 prispeva k ohranjanju celovitosti DNK v telesnih celicah.“
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Komisija in države članice so 13. maja 2015 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem kave C21 in navedeno trditvijo ni utemeljena.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Pri določanju ukrepov iz te uredbe so bile upoštevane pripombe, ki so jih vložniki poslali Komisiji v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
Done at Brussels, 24 August 2016.
Ukrepi iz te uredbe so v skladu z mnenjem Stalnega odbora za rastline, živali, hrano in krmo –
EFSA Journal 2014; 12(2):3574.
Člen 2
EFSA Journal 2011; 9(4):2054.
Ta uredba začne veljati dvajseti dan po objavi v Uradnem listu Evropske unije.
Minimum effective dose proposed by the applicant.
Ta uredba je v celoti zavezujoča in se neposredno uporablja v vseh državah članicah.
Minimum effective dose proposed by EFSA.
V Bruslju, 24. avgusta 2016
EFSA Journal 2015; 13(1):3953.
Za Komisijo
EFSA Journal 2015; 13(5):4095.
Predsednik
EFSA Journal 2015; 13(5):4098.
UL L 404, 30.12.2006, str. 9.
EFSA Journal 2015; 13(5):4097.
Najmanjši odmerek, pri katerem se pokaže učinek in ga je predlagal vložnik.
EFSA Journal 2015; 13(5):4094.
Najmanjši odmerek, pri katerem se pokaže učinek in ga je predlagala Agencija.
Nutrient, substance, food or food category
Zdravstvena trditev v zvezi s fruktozo je bila odobrena z Uredbo Komisije (EU) št. 536/2013 z dne 11. junija 2013 o spremembi Uredbe (EU) št. 432/2012 o seznamu dovoljenih zdravstvenih trditev na živilih, razen trditev, ki se nanašajo na zmanjšanje tveganja za nastanek bolezni ter na razvoj in zdravje otrok (UL L 160, 12.6.2013, str. 4).
Caffeine
PRILOGA
Caffeine helps to increase alertness *
Zavrnjene zdravstvene trditve
* For intakes of caffeine between 40 mg per serving and 75 mg per serving.
Vloga – ustrezne določbe Uredbe (ES) št. 1924/2006
Clarinol® and Tonalin®
Hranilo, snov, živilo ali kategorija živil
The consumption of Clarinol® or Tonalin® contributes to a reduction in body fat mass.
Trditev
SYNBIO® persists in the intestinal tract and favours the natural regularity contributing to maintain and improve human intestinal well-being'.
Referenčno mnenje Agencije za varnost hrane
FRUIT UP® reduces post-prandial blood glucose responses compared to high-glycaemic carbohydrates.
Zdravstvena trditev po členu 13(5), ki je utemeljena na novih znanstvenih dokazih in/ali vključuje zahtevo za zakonsko zaščito podatkov
A combination of pomegranate pomace extract and greater galangal rhizome powder
Kofein
A combination of standardised pomegranate pomace extract and greater galangal rhizome powder increases the number of motile spermatozoa in semen.
Kofein pomaga povečati budnost *.
Bifidobacterium bifidum CNCM I-3426 increases the proportion of healthy days by maintaining normal immune function in healthy adults during everyday life events such as moderate stress.
* Kofein v odmerku med 40 mg in 75 mg na porcijo.
Coffee C21 (coffee standardised by its content of caffeoylquinic acids, trigonelline andN-methylpyridinium)
Clarinol® in Tonalin®
Regular consumption of coffee C21 contributes to the maintenance of DNA integrity in cells of the body.
Uživanje izdelka Clarinol® ali Tonalin® prispeva k zmanjšanju telesne maščobe.
Following an application from Han-Asiabiotech GmbH, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Symbiosal® and lowering of blood pressure and reduced risk of hypertension (Question No EFSA-Q-2014-00366 [2]).
Družba Han-Asiabiotech GmbH je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi s Symbiosal® ter znižanjem krvnega tlaka in tveganja za hipertenzijo (vprašanje št.
The claim proposed by the applicant was worded as follows: ‘Symbiosal has been shown to lower the rising of blood pressure when used as a replacement of traditional table salt.
EFSA-Q-2014-00366 [2]).
The rising of blood pressure is a risk factor for high blood pressure (hypertension)’.
Vložnik je predlagal naslednjo trditev: „Symbiosal dokazano upočasnjuje zvišanje krvnega tlaka, kadar se uporablja kot nadomestek za tradicionalno namizno sol.
On 1 July 2015, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented a cause and effect relationship had not been established between the consumption of Symbiosal® instead of table salt and lowering of blood pressure.
Zvišanje krvnega tlaka je dejavnik tveganja za visok krvni tlak (hipertenzijo)“.
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Komisija in države članice so 1. julija 2015 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem Symbiosal® namesto namizne soli in znižanjem krvnega tlaka ni utemeljena.
Done at Brussels, 24 August 2016.
Ta uredba je v celoti zavezujoča in se neposredno uporablja v vseh državah članicah.
For the Commission
V Bruslju, 24. avgusta 2016
EFSA Journal 2015;13(7):4147.
UL L 404, 30.12.2006, str. 9.
ANNEX
EFSA Journal (2015);13(7):4147.
Article 14(1)(a) health claim referring to a reduction of a disease risk.
Referenčno mnenje Evropske agencije za varnost hrane
Symbiosal has been shown to lower the rising of blood pressure when used as a replacement of traditional table salt.
Zdravstvena trditev po členu 14(1)(a), ki se nanaša na zmanjšanje tveganja za nastanek bolezni.
amending Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods other than those referring to the reduction of disease risk and to children's development and health
o spremembi Uredbe (EU) št. 432/2012 o seznamu dovoljenih zdravstvenih trditev na živilih, razen trditev, ki se nanašajo na zmanjšanje tveganja za nastanek bolezni ter na razvoj in zdravje otrok
Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods [1], and in particular Article 13(4) thereof,
ob upoštevanju Uredbe (ES) št. 1924/2006 Evropskega parlamenta in Sveta z dne 20. decembra 2006 o prehranskih in zdravstvenih trditvah na živilih [1] in zlasti člena 13(4) Uredbe,
Regulation (EC) No 1924/2006 provides that health claims made on food are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.
Uredba (ES) št. 1924/2006 določa, da so zdravstvene trditve na živilih prepovedane, razen če jih Komisija v skladu z navedeno uredbo odobri in uvrsti na seznam dovoljenih trditev.
Pursuant to Article 13(3) of Regulation (EC) No 1924/2006 the Commission adopted Regulation (EU) No 432/2012 [2] which establishes a list of permitted health claims made on foods other than those referring to the reduction of disease risk and to children's development and health.
V skladu s členom 13(3) Uredbe (ES) št. 1924/2006 je Komisija sprejela Uredbo (EU) št. 432/2012 [2] o seznamu dovoljenih zdravstvenih trditev na živilih, razen trditev, ki se nanašajo na zmanjšanje tveganja za nastanek bolezni ter na razvoj in zdravje otrok.
The list of permitted health claims and their conditions of use are set out in the Annex to Regulation (EU) No 432/2012.
Seznam dovoljenih zdravstvenih trditev in pogoji za njihovo uporabo so določeni v Prilogi k Uredbi (EU) št. 432/2012.
Two claims have been authorised for meal replacement for weight control.
Dve trditvi sta bili dovoljeni za uporabo na nadomestnem obroku za nadzor nad telesno težo.
The conditions of use of those claims require that in order to bear them, the food should comply with specifications laid down in Commission Directive 96/8/EC [3].
Pogoji za uporabo navedenih trditev zahtevajo, da morajo živila, na katerih se navedeta trditvi, izpolnjevati specifikacije iz Direktive Komisije 96/8/ES [3].
Those claims were included in the list of permitted health claims pursuant to the favourable Opinion of the European Food Safety Authority (hereinafter ‘the Authority’) of 2010 (Question EFSA-Q-2008-2154, EFSA-Q-2008-2155 [4]) which found that a cause and effect relationship had been established between the consumption of meal replacements in substitution of regular meals and the maintenance of body weight after weight loss and also between the consumption of meal replacements in substitution of regular meals in the context of energy restricted diets and reduction in body weight.
Navedeni trditvi sta bili vključeni na seznam dovoljenih zdravstvenih trditev na podlagi pozitivnega mnenja Evropske agencije za varnost hrane (v nadaljnjem besedilu: Agencija) iz leta 2010 (vprašanji EFSA-Q-2008-2154 in EFSA-Q-2008-2155 [4]), ki je ugotovila, da je vzročna zveza med uživanjem nadomestnih obrokov namesto rednih obrokov in ohranjanjem telesne teže po zmanjšanju telesne teže ter med uživanjem nadomestnih obrokov namesto rednih obrokov pri energijsko omejeni prehrani in zmanjšanjem telesne teže utemeljena.
It stated that in order to bear the claims a food should contain a maximum of 250 kcal per serving and comply with specifications laid down in Directive 96/8/EC.
Navedla je, da morajo živila, na katerih se navedeta trditvi, vsebovati vsaj 250 kcal na obrok in izpolnjevati specifikacije iz Direktive 96/8/ES.
Directive 96/8/EC lays down compositional requirements for foods for use in energy-restricted diets for weight reduction which replace the whole or part of the total daily diet and specifies mandatory particulars which shall appear on the labelling of those products.
Direktiva 96/8/ES določa zahteve o sestavi živil, namenjenih za uporabo pri energijsko omejeni prehrani za zmanjšanje telesne teže, ki nadomeščajo celoto ali del dnevno zaužite hrane, in določa obvezne podatke, ki se navedejo na oznakah navedenih proizvodov.
It provides that as regards products which are presented as a replacement for one or more meals of the daily diet, the name under which they are sold is ‘Meal replacement for weight control’.
Določa, da mora biti ime, pod katerim se prodajajo proizvodi, predstavljeni kot nadomestki za enega ali več obrokov dnevnih obrokov hrane, „Nadomestni obrok za nadzor nad telesno težo“.
Regulation (EU) No 609/2013 of the European Parliament and of the Council [5] revises the legal framework applicable to foods for particular nutritional uses.
Z Uredbo (EU) št. 609/2013 Evropskega parlamenta in Sveta [5] je bil revidiran pravni okvir, ki se uporablja za živila s posebnim prehranskim namenom.